{
  "ticker": "MCRB",
  "company_name": "Seres Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03759041",
      "title": "A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Ulcerative Colitis",
      "start_date": "2018-12-19",
      "completion_date": "2021-10-13",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03183128",
      "title": "ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Clostridium Difficile Infection",
      "start_date": "2017-07-10",
      "completion_date": "2020-09-29",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02437487",
      "title": "SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Clostridium Difficile",
      "start_date": "2015-05",
      "completion_date": "2016-10",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02830542",
      "title": "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Clostridium Difficile Infection",
      "start_date": "2016-08",
      "completion_date": "2018-08",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02437500",
      "title": "Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)",
      "status": "APPROVED_FOR_MARKETING",
      "phase": "",
      "condition": "Clostridioides Difficile Infection",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02618187",
      "title": "A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Ulcerative Colitis",
      "start_date": "2016-01-13",
      "completion_date": "2018-01-26",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04995653",
      "title": "A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Allogeneic Hematopoietic Stem Cell Transplantation",
      "start_date": "2021-11-24",
      "completion_date": "2024-07-23",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03183141",
      "title": "ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Clostridioides Difficile Infection",
      "start_date": "2017-10-23",
      "completion_date": "2022-04-29",
      "enrollment": 0,
      "sponsor": "Seres Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03817125",
      "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Metastatic Melanoma",
      "start_date": "2019-01-28",
      "completion_date": "2022-03-04",
      "enrollment": 0,
      "sponsor": "Parker Institute for Cancer Immunotherapy"
    }
  ],
  "summary": {
    "total_trials": 9,
    "by_phase": {
      "PHASE2": 2,
      "PHASE3": 2,
      "PHASE1": 4,
      "": 1
    },
    "by_status": {
      "TERMINATED": 1,
      "COMPLETED": 7,
      "APPROVED_FOR_MARKETING": 1
    },
    "active_trials": 0,
    "completed_trials": 7,
    "conditions": [
      "Allogeneic Hematopoietic Stem Cell Transplantation",
      "Clostridioides Difficile Infection",
      "Clostridium Difficile",
      "Clostridium Difficile Infection",
      "Metastatic Melanoma",
      "Ulcerative Colitis"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:27.792615",
    "search_query": "Seres Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Seres+Therapeutics,+Inc."
  }
}